WUXI APPTEC held strong! Achieved 2024 performance guidance, expecting to achieve double-digit growth in revenue this year | Interpretations

In 2024, WUXI APPTEC's revenue and net profit saw a slight decline year-on-year, but it still achieved the performance guidance set at the beginning of last year; Despite the ongoing disturbances from the "Biotechnology Safety Act", customers and Orders still experienced substantial growth in 2024; WUXI APPTEC expects to achieve double-digit growth of 10-15% this year.

cls.cnMar 17 11:44 ET

Is the breakthrough path all in AI? Chain pharmacies are facing a wave of closures and an era of low profits.

① In 2024, particularly in the second half of the year, chain pharmacies will face a large-scale wave of closures, and leading chain pharmacies will generally enter a low-profit era. ② AI is also being assigned higher expectations in helping pharmacies reduce costs and increase efficiency. ③ Publicly available large models, due to a lack of support from vertical domain data, are still insufficient to support the actual Business Operation of pharmacies.

cls.cnMar 16 02:09 ET

Express News | Hong Kong Indexes Rally, Blue-Chip Stocks Rise; Some Industry-Leading Stocks Surge. U.S. Listed Chinese Equities Trade Higher in Overnight Trading

Moomoo 24/7Mar 13 23:34 ET

Trending Industry Today: WUXI BIO Leads Gains In CRO Stocks

Moomoo NewsMar 13 22:40 ET

National People's Congress representative, Zhao Jing of Shandong Buchang Pharmaceuticals: "The 'AI+' is reaching a critical point of explosion. It is recommended to utilize AI to empower the inheritance and innovation of Traditional Chinese Medicine | Two

① Zhao Jing, a representative of the National People's Congress and Vice Director of Shandong Buchang Pharmaceuticals, brought the proposal "Utilizing AI to Empower the Inheritance and Innovation of Traditional Chinese Medicine and Build a New Pattern of Development for Traditional Chinese Medicine with 'Asia Vets + Technology'" to this year's Two Sessions, aiming to promote the intelligent upgrade of the Traditional Chinese Medicine industry through AI technology. ② Zhao Jing stated that the development of large models like DeepSeek has indeed pushed the integration of Traditional Chinese Medicine and AI to a critical point of explosion.

cls.cnMar 6 20:48 ET

Nuvation Bio Enters Supply Agreement With Asymchem For Taletrectinib; 5-Year Initial Term With Automatic 3-Year Renewals

BenzingaMar 5 16:29 ET